Upfront treatment options set to expand for NSCLC patients with EGFR exon 20 inse ...

New study results highlight the potential of JNJ's RYBREVANT-LAZCLUZE combination to improve long-term outcomes in EGFR-mutated lung cancer.

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a ...

The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 ...

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for ...

First-line treatment with sunvozertinib significantly prolongs PFS compared to chemotherapy in advanced or metastatic NSCLC with EGFR insertions.

Dr. Rodriguez describes the current period in EGFR-positive lung cancer as one of active change in the first-line landscape: ...

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...

Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...

Could a daily pill after chemoradiation keep lung cancer from returning? The News On 6 weekend team provides a comprehensive look at updated news events, a detailed and up-to-the-minute weather ...